Navigation Links
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Date:10/26/2007

eeting pre-defined Responder criteria (p=0.009).

In the study, 229 patients with ADHD aged 18-65 years were randomized to receive CONCERTA(R) 36-108 mg/day or placebo, for seven weeks. The final analysis set contained data from 226 patients(a). Patients in the CONCERTA(R) group received a starting dose of 36 mg/day and the dose was increased in 18 mg increments every seven days (+/-2 days) for up to five weeks until response (AISRS scores decreased by 30% and CGI-I rating of 1 "very much" or 2 "much" improved) was achieved or titration to the maximum dose of 108 mg. The dose could be reduced one time during the study for tolerability reasons. The mean final dose was 67.7 mg/day.

Adverse events were reported by 93 (84.5%) of patients in the CONCERTA(R) group compared with 74 (63.8%) in the placebo group. The most commonly reported adverse events with CONCERTA(R) included decreased appetite (25.5%), headache (25.5%), dry mouth (20%), anxiety (16.4%), nausea (12.7%), increased blood pressure (10%), insomnia (9.1%), initial insomnia (7.3%), increased heart rate (7.3%), bruxism (6.4%), irritability (6.4%) and muscle tightness (6.4%). There were no serious treatment emergent adverse events reported and 16 (14.5%) and 6 (5.2%) subjects in the CONCERTA(R) and placebo groups, respectively, discontinued due to adverse events.

Today's data presentation included interim results from a long-term, open-label safety study. A similar dose titration protocol was used as in the double-blind study during the first weeks of the study after which the dose was flexible within the range of 36 to 108 mg. Interim results show that CONCERTA(R) was well tolerated in an adult population with ADHD in a dose range from 36mg to 108 mg per day for up to six months.

About ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is a common and treatable neuropsychiatric condition, which includes inattention, hyperactivity and impulsivity. According to the National Institut
'/>"/>

SOURCE McNeil Pediatrics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  Medical Science Liaisons serve as a ... the healthcare sector. As the impact of technology in ... how Medical Science Liaisons (MSLs) interact with physicians and ... the tablet to not only share important disease and ... thought leader interactions across geographies and therapeutic areas. ...
(Date:8/22/2014)... 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... instrument for any modern science laboratory as ... materials. It can be broadly classified into ...
(Date:8/22/2014)... Research and Markets ( ... the  "Global Operating Room Equipment Market 2014-2018" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating room is ... a healthcare facility used to perform surgical ... equipment, which ensures patient care and enhanced ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... June 13 Telmisartan, an angiotensin receptor blocker, ... been studied in clinical trials in more than 50,000 patients. ... market exposure of 34.5 million patient years. Convincing safety data ... the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which ...
... Scientists from the Barbara Ann Karmanos Cancer Institute in ... agents used to promote bone health and inhibit resorption, may ... early stage breast cancer who take them for their anti-osteoporosis ... Society of Clinical Oncology Annual Meeting. , ...
Cached Medicine Technology:Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 2Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 3Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 4Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 5Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
(Date:8/22/2014)... Hudson County, NJ (PRWEB) August 22, 2014 ... that a leading specialist in Internal Medicine, Geriatrics, ... joined the network, CarePoint Health Medical Group. Their ... of highly skilled and experienced physicians comprise CarePoint ... doctors and practices in Hudson County, representing a ...
(Date:8/22/2014)... News) -- Back-to-school time provides an opportunity for parents ... family schedules, an expert suggests. "Forget New Year,s ... also be the start of a new fitness and ... kinesiology at the University of the Sciences in Philadelphia, ... extracurricular activities likely to build up, "it,s important for ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... of the National Commission on Macroeconomics and Health, K ... to make mandatory a comprehensive Universal Health Insurance System ... of 9 % of the GDP on health and ... growth and provision of basic infrastructural needs. ,Inaugurating ...
... The FDA has sent shock waves in the industry ... Nov. 8 from the U.S. Food and Drug Administration ... for qualified health claims for lycopene, tomatoes, and tomatoes-based ... lycopene (tomatoes, tomato-based foods containing lycopene) may reduce the ...
... Millennium Development Goals Memorandum signed between 189 countries from ... better health conditions to people in poor countries have ... these people had been reported in the Journal British ... make meaningful progress on the strategy aims - the ...
... various factors which are responsible for malaria infection and ... link to difference in genetic makeup between different individuals//. ... and colleagues were interested in the relative contributions of ... malaria. To estimate the overall contribution of genetic factors ...
... claimed 10 lives while over 3,000 people were suffering ... government officer said Friday//., ,"Nearly 3,000 tribal people ... have been in the grip of malaria and typhoid. ... three days," the district's acting collector Amir Ali said ...
... in the US have discovered a hormone that regulates ... the future//. ,Researchers at Stanford University, California, looked ... that codes for ghrelin, an appetite-boosting hormone. ... same protein precursor that produced ghrelin. The researchers say ...
Cached Medicine News:Health News:Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare 2Health News:Programs for development of health in poor countries not effective 2Health News:Researchers finding link between malaria susceptibility and genetic makeup 2
... Crossover system of implants and instruments provides ... posterior rod construct in the thoracic and ... system are available in three size ranges: ... can be used with the Isola, Pediatric ...
Portable ultrasound doppler system for peripheral and transcranial investigation....
Multiwindow transcranial and peripheral Doppler system....
Bi-Directional doppler volume flowmeter....
Medicine Products: